- Reuters reports that the FDA is working on "about a dozen" policies aimed at making it easier for biosimilars to gain a foothold in the U.S. market.
- Unlike Europe where biosimilars have made inroads, U.S. drugmakers have been successful in blocking the entry of the lower-priced competition.
- Commissioner Scott Gottlieb, M.D. has criticized the industry for its "Kabuki drug-pricing constructs." One action the agency intends to pursue is making it more difficult for biologic developers to tweak existing patents in order to extend coverage.
- He is also concerned with the competition-stifling consolidation in the drug supply chain.
- Selected tickers: (XLV +0.8%)(IHE)(XBI -0.6%)(AMGN +0.1%)(BIIB +2.4%)(JNJ +0.8%)(OTCQX:RHHBY +1.4%)(ABBV +4.1%)(AGN +3.9%)(AZN +2.2%)(BMY +0.7%)(GSK +3.3%)(LLY +2.1%)(MRK +2%)(NVS +2.8%)(NVO +1.8%)(PFE +1.4%)(VRX +1.7%)(TEVA +1.2%)(MYL +1.8%)(CHRS +3%)
- Now read: Will Analysts Abandon Allergan On Esmya Headwinds?
Original article